Advancing Life and Liberty Through Action

Censoring Medical Data

Jul 29, 2020

America’s Frontline Doctors took the internet by storm before they were shut down by Facebook, Twitter, Google search results, and YouTube. Even Squarespace erased their organization’s home page. Below is the heart of the message they were trying to get out about hydroxychloroquine (HCQ).

These doctors had the gall to cite 18 medical studies and sources that discuss the safety and efficacy of hydroxychloroquine in treating COVID-19. Even if you disagree with their conclusions, ask yourself, are you comfortable with Big Tech having complete power to silence medical doctors that are successfully treating patients in the middle of a pandemic? (If not, sign LCA's petition to fight for their freedom.)

These doctors deserve to have their voices heard and for the free American public to make up their own minds. America’s Frontline Doctors wrote the following on their page.

There are only two things that must be considered regarding a medication: is it safe and does it work? HCQ is amongst the safest of all prescription drugs in the USA and that is why across much of the world it is sold over the counter.

Keep in mind that even over-the-counter aspirin is not recommended for pregnant women. Neither is Ibuprofen. But MD Edge writer Jeff Evens wrote (PDF) the following about hydroxychloroquine:

“The anti-inflammatory compound hydroxychloroquine appears to be relatively safe during pregnancy, according to a small number of studies totaling about 250 patients.” “Now, many physicians who treat about four to five pregnant women with connective tissue disorder each year regularly prescribe antimalarials to such patients,” and “In fact, 69% of 52 physicians who responded to a survey about the use of antimalarials during pregnancy said they continued antimalarials in pregnancy sometimes, often, or always (J. Rheumatol. 2002;29:700–6).”

It appears that taking the correct dose of hydroxychloroquine is even safer than popping a Tylenol. America’s Frontline Doctors went on to write:

The safety record of HCQ is indisputable. But now seven months into the pandemic there is overwhelming evidence accumulating that HCQ is also effective for Covid-19. There are dozens of studies demonstrating its effectiveness from all around the world. From China to France to Saudi Arabia to Iran to Italy to India to New York City to Michigan to Brazil.

This is not surprising. As far back as [2005], chloroquine (CQ) the first cousin of HCQ and previously known to be effective against SARS-CoV-1, was stated by China to be a treatment for Covid-19.

  • February 19, 2020 China: “The drug [chloroquine] is recommended to be included in the next version of the Guidelines for the Prevention, Diagnosis, and Treatment of Pneumonia Caused by COVID-19 issued by the National Health Commission of the People’s Republic of China for the treatment of COVID-10 infection in larger populations in the future.”[i]
  • March 4, 2020: France: “The first results obtained from more than 100 patients show the superiority of chloroquine compared with treatment of the control group in terms of reduction of exacerbation of pneumonia, duration of symptoms and delay of viral clearance all in the absence of severe side effects.”[ii]
  • March 20, 2020: New York: 1450 patients. 1045 mild and not requiring meds (all recovered), 405 treated with HCQ + AZM + Zinc of which six were hospitalized and two died.[iii]
  • March 22, 2020: India: The country of India recommends HCQ prophylaxis broadly.[iv]
  • March 22, 2020: China: “Among patients with Covid-19, HCQ could significantly shorten time to complete recovery and promote the absorption of pneumonia.”[v]
  • April 11, 2020: France: All patients [treated with HCQ + AZM] improved clinically except [two]... A rapid fall of nasopharyngeal viral load was noted. ... Patients were able to be rapidly discharged from IDU [Infectious Disease Unit]...”[vi]
  • April 13, 2020: NY: 54 long-term care/nursing home patients received HCQ+ Doxycycline and only 5.6% died. (this population can have >50% mortality)[vii][viii]
  • April 17, 2020: Brazil: Of 636 symptomatic high-risk outpatients, only 1.9% of those treated needed hospitalization vs., 5.4% of the untreated.[ix]
  • April 21, 2020: 16 countries: “The difference in dynamics of daily deaths is so striking that we believe that the urgency context commands presenting the analysis ...”[x][xi]
  • April 24, 2020: Iran: Hydroxychloroquine ...can be potential treatment options.[xii]
  • April 30, 2020: Saudi Arabia: “Chloroquine and hydroxychloroquine have antiviral characteristics in vitro. The findings support the hypotheses that these drugs have efficacy in the treatment of COvid-19.”[xiii]
  • May 15, 2020: China: We found that fatalities are 18.8% in the HCQ group, significantly lower than 47.4% in the non-HCQ group. These data demonstrate that addition of HCQ on top of the basic treatments is highly effective in reducing the fatality of critically ill patients of Covid-19 through attenuation of inflammatory cytokine storm. Therefore, HCQ should be prescribed as a part of treatment for critically ill Covid-19 patients, with possible outcome of saving lives.[xiv]
  • May 16, 2020: France: 1061 Covid-positive patients treated with HCQ+AZM “no cardiac toxicity was observed” and “good clinical outcome and virological cure were seen in 92%.[xv]
  • June 6, 2020: France: “In conclusion, a meta-analysis of publicly available clinical reports demonstrates that chloroquine ... reduces mortality by a factor 3 in patients infected with Covid-19.”[xvi]
  • June 20, 2020: India: “Consumption of four or more maintenance doses of HCQ was associated with a significant decline in the odds of getting infected... This study provides actionable information for policymakers to protect healthcare workers at the forefront of Covid-19 response.”[xvii][xviii]
  • June 29, 2020: Portugal: The odds ration of [Covid-19] infection in patient with chronic treatment with HCQ is half.[xix]
  • June 29, 2020: Detroit: “In this multi-hospital assessment, when controlling for Covid-19 risk factors, treatment with HCQ alone and in combination with AZM was associated with reduction in Covid-19 mortality.”[xx]
  • June 30, 2020: NYC: 6493 patients who had laboratory confirmed Covid- 19 with clinical outcomes between March 13-April 17, 2020 who were seen in 8 hospitals and 400 clinics in the NYC metropolitan area. “Hydroxychloroquine use was associated with decreased mortality.”[xxi]
  • July 3, 2020: NY: Covid-positive patients treated with HCQ + AZM + Zinc vs. untreated.[xxii]
  • hospitalized: treated 2.8% vs. untreated 15.4%
  • death: treated 0.7% vs. untreated 3.5%,
  • No cardiac side effects
  • 5x less all-cause deaths

Where have the World Health Organization, the Centers for Disease Control, and American doctors been for the last five months? This information from America’s Frontline Doctors was taken down by Squarespace, censored by Big Tech, and silenced by social media.

If you want to push back today, send your urgent fax to Congress and the FCC to stop the censorship.



Liberty Counsel Action works to empower patriots across America to defend our nation's future. You can receive our free email alerts with breaking news and legal analysis of what is really happening on Capitol Hill and around the world. Sign up now.

LCA advances religious liberty, the sanctity of human life, and the family through law and policy education, training and advocacy. We depend on your support to make a difference at the federal, state and local levels.

Click here to GIVE NOW.




 

[i]Gao, Jianjun, Zhenzue Tian, and Xu Yang. BioScience Trends. Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. (Received: 2020, February 18. Published: 2020, March 16). https://www.jstage.jst.go.jp/article/bst/14/1/14_2020.01047/_article.

[ii]
Colson, Philippe, Jean-Marc Rolan, Jean-Christophe Lagier, Philippe Brouqui, and Didier Raoult. National Center for Biotechnology Information: National Institutes for Health. Chloroquine and hydroxychloroquine as available weapons to fight COVID-19. (2020, March 4). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7135139.

[iii]Risch, Harvey A. American Journal of Epidemiology in partnership with Johns Hopkin Bloomberg School of Public Health and Oxford Academic. Early Outpatient Treatment of Symptomatic, High-Risk Covid-19 Patients that Should be Ramped-Up Immediately as Key to the Pandemic Crisis. (2020 May 27). https://academic.oup.com/aje/article/doi/10.1093/aje/kwaa093/5847586.

[iv]Bhargava, Balram. Ministry of Health and Family Welfare: Government of India. Advisory of the use of hydroxyl-chloroquine as prophylaxis for SARS-CoV-2 infection. (2020, March 22). https://www.mohfw.gov.in/pdf/AdvisoryontheuseofHydroxychloroquinasprophylaxisforSARSCoV2infection.pdf.

[v]Chen. Zhaowei, Jijia Hu, Zongwei Zhang, Shan Jiang, Shoumeng Han, Dandan Yan, Ruhong Zhuang, Ben Hu, and Zhan Zhang. MedRXIV in partnership with Yale, BMJ (Formerly the British Medical Journal) and the Cold Spring Harbor Laboratory.  Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial. (2020, April 10). https://www.medrxiv.org/content/10.1101/2020.03.22.20040758v3.

[vi]Gautret, Philippe. Jean-Christophe Lagier, Philippe Parola, Van Thuan Hoang, Line Meddeb, Jacques Sevestre, Morgane Mailhe, Barbara Doudier, Camille Aubry, Sophie Amrane, Piseth Seng, Marie Hocquart, Carole Eldin, Julie Finance,  Vera Esteves Vieira, et al. Science Direct. Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: A pilot observational study. (Received: 2020, April 3, Published: 2020, April 11). https://www.sciencedirect.com/science/article/pii/S1477893920301319.

[vii]ABC News. Coronavirus News: Long Island doctors embrace combination drug therapy in fighting COVID-19. (2020 April 13). https://abc7ny.com/coronavirus-treatment-long-island-news-nassau-county/6093072/.

[viii]Yu, Bo, Chenze Li, Peng Chen, Ning Zhou, Luyun Wang, Jia Li, Hualiang Jiang, and Dao-Wen Wang. PubMed.gov of National Library of Medicine: National Institutes of Health. Low dose of hydroxychloroquine reduces fatality of critically ill patients with COVID-19. (2020, May 15). https://pubmed.ncbi.nlm.nih.gov/32418114/.

[ix]Rodrigo  Barbosa  Esper  M.D., Ph.D.,  Rafael  Souza  da  Silva  M.D.,  Fernando Teiichi Costa Oikawa M.D., Ph.D., Marcelo Machado Castro M.D., Alvaro Razuk-Filho M.D., Ph.D.,  Pedro  Benedito  Batista  Junior  M.D.,  Sergio  Wilhelm  Lotze  M.D.,  Cleber Nunes  da  Rocha  M.D.,  Roberto  de  Sá  Cunha  Filho  M.D.,  Saulo  Emanuel  Barbosa de  Oliveira  M.D,  Philipe  Leitão  Ribeiro,  M.D.,  Valéria  Cristina  Vigar  Martins  M.D., Fernando Silva Braga Bueno M.D., Priscila Ligeiro Gonçalves Esper M.D., and Eduardo Fagundes Parrillo M.D.. Empirical treatment with hydroxychloroquine and azithromycin for suspected cases of COVID-19 followed-up by telemedicine. (Accessed 2020, July 7). https://pgibertie.files.wordpress.com/2020/04/2020.04.15-journal-manuscript-final.pdf.

[x]Izoulet, Maxime. SSRN (formerly known as Social Science Research Network). Countries which Primarily Use Antimalarial Drugs As COVID-19 Treatment See Slower Dynamic of Daily Deaths. (2020, April 21). https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3575899.

[xi]Izoulet, Maxime. MedRXIV in partnership with Yale, BMJ (Formerly the British Medical Journal) and the Cold Spring Harbor Laboratory. National Consumption of Antimalarial Drugs and COVID-19 Deaths Dynamics : an Ecological Study. (2020, May 28). https://www.medrxiv.org/content/10.1101/2020.04.18.20063875v2.

[xii]Ashraf, Mohammad. Nasim Shokouhi, Elham Shirali, Fateme Davari-tanha, Omeed Memar, Alireza Kamalipour, Ayein Azarnoush, Avin Mabadi, Adele Ossareh, Milad Sanginabadi, Talat Azad, Leila Aghaghazvini, Sara Ghaderkhani, Tahereh Poordast, Alieh Pourdast, and Pershang Nazemi. ResearchGate. COVID-19 in Iran, a comprehensive investigation from exposure to treatment outcomes. (2020, May). https://www.researchgate.net/publication/341197843_COVID-19_in_Iran_a_comprehensive_investigation_from_exposure_to_treatment_outcomes.

[xiii]Meo, Sultan Ayoub. D.C. Klonoff, and J. Akram. European Review for Medical and Pharmacological Sciences. Efficacy of chloroquine and hydroxychloroquine in the treatment of COVID-19. (2020). https://www.europeanreview.org/wp/wp-content/uploads/4539-4547.pdf.

[xiv]Yu, Bo, Chenze Li, Peng Chen, Ning Zhou, Luyun Wang, Jia Li, Hualiang Jiang, and Dao-Wen Wang. PubMed.gov of National Library of Medicine: National Institutes of Health. Low dose of hydroxychloroquine reduces fatality of critically ill patients with COVID-19. (2020, May 15). https://pubmed.ncbi.nlm.nih.gov/32418114/.

[xv]Million, Matthieu. Jean-Christophe Lagier, Philippe Gautret, et al. Méditerranée Infection. Early treatment of 1061 COVID-19 patients with hydroxychloroquine and azithromycin, Marseille, France. (Accessed 2020, July 29). https://www.mediterranee-infection.com/wp-content/uploads/2020/04/MS.pdf.

[xvi]Million, Matthieu. Philippe Gautretac, Philippe Colson, Yanis Roussel, Gregory Dubourg, Eric Chabriere, Stéphane Honore, Jean-Marc Rolain, Florence Fenollar,  Pierre-Edouard Fournier, Jean-Christophe Lagier, Philippe Parola, Philippe Brouqui,  and Didier Raoult. Science Direct. Clinical Efficacy of Chloroquine derivatives in COVID-19 Infection: Comparative meta-analysis between the Big data and the real world. (2020, June 6). https://www.sciencedirect.com/science/article/pii/S2052297520300615.

[xvii]Chatterjee, Pranab. Tanu Anand, Kh Jitenkumar Singh, Reeta Rasaily, Ravinder Singh, Santasabuj Das, Harpreet Singh, Ira Praharaj, Raman R Gangakhedkar, Balram Bhargava, and Samiran Panda. Indian Journal of Medial Research: Indian Council of Medial Research. Healthcare workers & SARS-CoV-2 infection in India: A case-control investigation in the time of COVID-19. (2020, June 20). http://www.ijmr.org.in/article.asp?issn=0971-5916;year=2020;volume=151;issue=5;spage=459;epage=467;aulast=Chatterjee.

[xviii]Chatterjee, Pranab. Tanu Anand, Kh Jitenkumar Singh, Reeta Rasaily, Ravinder Singh, Santasabuj Das, Harpreet Singh, Ira Praharaj, Raman R Gangakhedkar, Balram Bhargava, and Samiran Panda. National Center for Biotechnology Information at the National Library of Medicine of the National Institutes of Health. Healthcare workers & SARS-CoV-2 infection in India: A case-control investigation in the time of COVID-19. (2020, July 3). https://www.ncbi.nlm.nih.gov/research/coronavirus/publication/32611916.

[xix]Ferreira, Antonio. Antonio Oliveira-e-Silva, and Paulo Bettencourt. MedRXIV in partnership with Yale, BMJ (Formerly the British Medical Journal) and the Cold Spring Harbor Laboratory. Chronic treatment with hydroxychloroquine and SARS-CoV-2 infection. (2020, June 29). https://www.medrxiv.org/content/10.1101/2020.06.26.20056507v1.

[xx]Arshada, Samia. Paul Kilgore, Zohra S. Chaudhry, Gordon Jacobsen, Dee Dee Wang, Kylie Huitsing, Indira Brar, George J. Alangaden, Mayur S. Ramesh, John E. McKinnon, William O’Neill, Marcus Zervos, and Henry Ford COVID-19 Task Force. International Journal of Infectious Diseases. Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19. (Received first version: 2020, May 28, Published: 2020, June 29). https://www.ijidonline.com/action/showPdf?pii=S1201-9712%2820%2930534-8.

[xxi]Mikami, T., Miyashita, H., Yamada, T. et al. Journal of General Internal Medicine. Risk Factors for Mortality in Patients with COVID-19 in New York City. (Published 2020, June 30). https://link.springer.com/article/10.1007%2Fs11606-020-05983-z.

[xxii]Scholz, Martin. Roland Derwand , and Vladimir Zelenko. Preprints. COVID-19 Outpatients – Early Risk-Stratified Treatment with Zinc Plus Low Dose Hydroxychloroquine and Azithromycin: A Retrospective Case Series Study. (Received: 2020, June 30, Published: 2020, July 3). https://www.preprints.org/manuscript/202007.0025/v1.

TAKE ACTION